Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.

ABSTRACT:

Purpose

Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19⁺ B cell malignancies, the application of this approach to solid tumors is challenging. The goal of this proof-of-concept study was to investigate whether loading of CD19-CAR T cells (CART19) with anti-HER2 or anti-EGFR bispecific antibodies (BiAb) will target HER2⁺/EGFR⁺ CD19^- targets and signal the intracellular domain of CAR without engaging antigen-specific CD19 ScFv of CAR T cells.

Methods

We used CART19 armed with anti-CD3 (OKT3) × anti-HER2 BiAb (HER2Bi) or anti-CD3 (OKT3) × anti-EGFR BiAb (EGFRBi) to evaluate the cytotoxicity directed at HER2 or EGFR expressing cancer cell l

SUBMITTER: Thakur A 

PROVIDER: S-EPMC7375514 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature